Home

Mark Eisner

CIK 1834161 · EVP and Chief Medical Officer · last filed 2026-06-26

Mark Eisner is an EVP and Chief Medical Officer who has filed 35 SEC Form 4 insider transactions across 4 companies since 2020. The most recent filing, for JBIO, was dated Jun 26, 2026. Across all open-market trades the lifetime net is −$720.6K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.8M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$1.78M

Companies

4

Total Filings

35

Lifetime Open-Market Net

-$720.6K

Filer Profile

Reported Address
C/O FIBROGEN, INC.
409 ILLINOIS STREET
SAN FRANCISCO, CA 94158
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
JBIO Director — $19.90 — $0 1 2026-06-26
ZURA Director — $6.23 — $0 2 2026-06-22
VIR EVP and Chief Medical Officer 155,913 $11.38 $1.78M -$106.3K 5 2026-02-26
KYNTRA BIO, INC. (FGEN) Delisted EVP, Chief Medical Officer 6,397 $9.75 $62.4K -$614.3K 19 2023-09-08

Recent Filings

35 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-26 JBIO Grant (A) — $0 EDGAR
2026-06-22 ZURA Grant (A) — $0 EDGAR
2026-04-30 VIR Notice (144) −88,958 -$916.3K EDGAR
2026-02-26 VIR Sell (S) −3,505 -$34.0K EDGAR
2026-02-25 VIR Notice (144) −1,889 -$18.5K EDGAR
2026-02-24 VIR Notice (144) −1,616 -$15.4K EDGAR
2026-02-24 ZURA Grant (A) — $0 EDGAR
2026-02-24 VIR Mixed +52,911 -$15.6K EDGAR
2026-02-23 VIR Notice (144) −2,089 -$15.6K EDGAR
2025-07-17 VIR Notice (144) −3,586 -$19.4K EDGAR
Showing 1–10 of 35
Page 1 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.